Login to Your Account

Stock Dips 14% on Opening Day

Merrimack Pharmaceuticals Aims to Raise $100M in IPO

By Catherine Shaffer
Staff Writer

Friday, March 30, 2012
Merrimack Pharmaceuticals Inc., which has initiated six new clinical trials since August 2011, priced an initial public offering (IPO) of 14.3 million shares of common stock at $7 per share, for a total anticipated raise of about $100 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription